- Always striving to take the
road less traveled
- Disease and health have no national boundaries and Otsuka’s line of thought about how to tackle unaddressed medical needs also takes us far beyond the boundaries of conventional thinking. One of our internal golden rules is ‘All For Creativity.’ We operationalize this by focusing exclusively on products that only Otsuka can imagine and avoiding fast-follower products or copycat generic drugs.
It has been 43 years since Otsuka Pharmaceutical established its first research institute for therapeutic drugs in 1971. Today, the company’s researchers are persevering with drug discovery research into much-awaited treatments for difficult diseases that affect people around the world.
Building on its blockbuster antipsychotic drug ABILIFY, which took 25 years to research and develop and is now available in 60 countries and regions. In 2013 Otsuka Pharmaceutical launched Abilify
Maintena in the U.S. This new product, a once-monthly, extended-release injection, provides a new treatment to help prevent relapse in patients with schizophrenia, a choice for patients who have difficulty taking pills every day.
Tuberculosis is a global public health problem, well-suited to Otsuka’s research on antimicrobial agents underway since the research institute was established, as well as our passion to take on big challenges. Otsuka Pharmaceutical has been grappling with this difficult disease for over 30 years, and has successfully developed and introduced a drug for difficult-to-treat, multidrug-resistant tuberculosis. The company has also successfully developed and launched a treatment for autosomal dominant polycystic kidney disease (ADPKD), a genetic disease for which there was previously no treatment.
Ever since our chairman Akihiko Otsuka established the research institute for in-house development of therapeutic drugs, Otsuka Pharmaceutical’s researchers have continued to embrace their mission with high aspirations, great passion, and steadfast dedication. All of their efforts reflect their commitment to patients.